↓ Skip to main content

Dove Medical Press

Article Metrics

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection

Overview of attention for article published in Hepatic medicine evidence and research, September 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
2 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
27 Mendeley
Title
Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
Published in
Hepatic medicine evidence and research, September 2016
DOI 10.2147/hmer.s91709
Pubmed ID
Authors

Christopher Bowlus

Abstract

Primary biliary cholangitis (PBC), previously known as primary biliary "cirrhosis", is a rare autoimmune liver disease characterized by the hallmark autoantibodies to mitochondrial antigens and immune-mediated destruction of small bile duct epithelial cells leading to cholestasis and cirrhosis. Surprisingly, while immune modulators have not been effective in the treatment of PBC, supplementation with the hydrophilic bile acid (BA) ursodeoxycholic acid (UDCA) has been demonstrated to slow the disease progression. However, a significant minority of PBC patients do not have a complete response to UDCA and remain at risk of continued disease progression. Although the mechanisms of action are not well understood, UDCA provided proof of concept for BA therapy in PBC. Obeticholic acid (OCA), a novel derivative of the human BA chenodeoxycholic acid, is a potent agonist of the nuclear hormone receptor farnesoid X receptor, which regulates BA synthesis and transport. A series of clinical trials of OCA in PBC, primarily in combination with UDCA, have established that OCA leads to significant reductions in serum alkaline phosphatase that are predicted to lead to improved clinical outcomes, while dose-dependent pruritus has been the most common adverse effect. On the basis of these studies, OCA was given conditional approval by the US Food and Drug Administration with plans to establish the long-term clinical efficacy of OCA in patients with advanced PBC.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 4%
Unknown 26 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 22%
Student > Ph. D. Student 3 11%
Unspecified 3 11%
Student > Postgraduate 2 7%
Other 2 7%
Other 9 33%
Unknown 2 7%
Readers by discipline Count As %
Medicine and Dentistry 10 37%
Pharmacology, Toxicology and Pharmaceutical Science 4 15%
Unspecified 4 15%
Biochemistry, Genetics and Molecular Biology 3 11%
Agricultural and Biological Sciences 2 7%
Other 2 7%
Unknown 2 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 March 2017.
All research outputs
#796,933
of 9,222,312 outputs
Outputs from Hepatic medicine evidence and research
#2
of 40 outputs
Outputs of similar age
#32,761
of 257,132 outputs
Outputs of similar age from Hepatic medicine evidence and research
#1
of 3 outputs
Altmetric has tracked 9,222,312 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 40 research outputs from this source. They receive a mean Attention Score of 1.8. This one scored the same or higher as 38 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 257,132 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them